HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis.
The conventional treatment for paracoccidioidomycosis, the most prevalent mycosis in Latin America, involves long periods of therapy resulting in sequels and high frequency of relapses. The search for new alternatives of treatment is necessary. Previously, we have demonstrated that the hsp65 gene from Mycobacterium leprae shows prophylactic effects against murine paracoccidioidomycosis. Here, we tested the DNAhsp65 immunotherapy in BALB/c mice infected with Paracoccidioides brasiliensis, the agent of paracoccidioidomycosis. We observed an increase of Th1 cytokines accompanied by a reduction in fungal burden and pulmonary injury. These results provide new prospects for immunotherapy of paracoccidioidomycosis and other mycoses.
Ribeiro
Alice M
AM
Laboratory of Pathology, Faculty of Medicine, University of Brasília, 70910-900 Brasilia, DF, Brazil.
Bocca
Anamelia L
AL
Amaral
André C
AC
Souza
Ana Camila C O
AC
Faccioli
Lúcia H
LH
Coelho-Castelo
Arlete A M
AA
Figueiredo
Florêncio
F
Silva
Célio L
CL
Felipe
Maria Sueli S
MS
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D018834:Chaperonin 60 / Q000235:genetics / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods*; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009166:Mycobacterium leprae / Q000235:genetics / Q000276:immunology*; D010228:Paracoccidioides / Q000276:immunology; D010229:Paracoccidioidomycosis / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
D001426:Bacterial Proteins; D018834:Chaperonin 60; D016207:Cytokines; D019444:Vaccines, DNA; C074119:heat-shock protein 65, Mycobacterium